Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

Howard L. Ritter, Richard J. Gralla, Stephen W. Hall, J. K. Wada, Carl Friedman, Linda Hand, David Fitts

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.

Original languageEnglish (US)
Pages (from-to)87-93
Number of pages7
JournalCancer Investigation
Volume16
Issue number2
StatePublished - 1998
Externally publishedYes

Fingerprint

Granisetron
Nausea
Cisplatin
Vomiting
Drug Therapy
Antiemetics
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ritter, H. L., Gralla, R. J., Hall, S. W., Wada, J. K., Friedman, C., Hand, L., & Fitts, D. (1998). Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Investigation, 16(2), 87-93.

Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. / Ritter, Howard L.; Gralla, Richard J.; Hall, Stephen W.; Wada, J. K.; Friedman, Carl; Hand, Linda; Fitts, David.

In: Cancer Investigation, Vol. 16, No. 2, 1998, p. 87-93.

Research output: Contribution to journalArticle

Ritter, HL, Gralla, RJ, Hall, SW, Wada, JK, Friedman, C, Hand, L & Fitts, D 1998, 'Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy', Cancer Investigation, vol. 16, no. 2, pp. 87-93.
Ritter, Howard L. ; Gralla, Richard J. ; Hall, Stephen W. ; Wada, J. K. ; Friedman, Carl ; Hand, Linda ; Fitts, David. / Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. In: Cancer Investigation. 1998 ; Vol. 16, No. 2. pp. 87-93.
@article{1a045cabefea43ab8df6bda748af7144,
title = "Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy",
abstract = "The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40{\%} and 49{\%} of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42{\%} and 38{\%} of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.",
author = "Ritter, {Howard L.} and Gralla, {Richard J.} and Hall, {Stephen W.} and Wada, {J. K.} and Carl Friedman and Linda Hand and David Fitts",
year = "1998",
language = "English (US)",
volume = "16",
pages = "87--93",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

AU - Ritter, Howard L.

AU - Gralla, Richard J.

AU - Hall, Stephen W.

AU - Wada, J. K.

AU - Friedman, Carl

AU - Hand, Linda

AU - Fitts, David

PY - 1998

Y1 - 1998

N2 - The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.

AB - The safety and efficacy of granisetron (10 μg/kg and 40 μg/kg) were evaluated during a second (n = 393) and third (n = 200) cycle of chemotherapy in this multicenter, double-blind, randomized, parallel-group study. Granisetron was administered as a single intravenous dose before the start of cisplatin chemotherapy (≤60 mg/m2). Total control (no vomiting, no retching, no nausea, and no use of antiemetic rescue medications) after the first 24 hr following chemotherapy was achieved in 40% and 49% of patients in cycles 2 and 3, respectively, for the 10 μg/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40μg/kg group. Both dose levels of granisetron were well tolerated. The results demonstrate comparable efficacy between the 10 μg/kg and 40 μg/kg doses of granisetron in preventing cause and vomiting during repeat cycles of high-dose cisplatin- based chemotherapy. The results of this study show that granisetron 10 μg/kg is safe and well tolerated, and remains effective with repeat cycle use.

UR - http://www.scopus.com/inward/record.url?scp=15444340358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444340358&partnerID=8YFLogxK

M3 - Article

C2 - 9512674

AN - SCOPUS:15444340358

VL - 16

SP - 87

EP - 93

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -